← Eichor
Condition: Olverembatinib Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Olverembatinib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06754267Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Phil
EARLY_Phase 1 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07074496A Study of Olverembatinib in SDH-deficient GIST.
Phase 3 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06640361Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT07282093Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06757855Study of Olverembatinib (HQP1351) in Patients With CP-CML
Phase 3 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06423911A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With New
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06220487Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · Xijing Hospital · NCT06082934Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481228Olverembatinib for FGFR1-rearranged Neoplasms
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05521204Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chroni
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06817720A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Phase 3 · 90 location(s) · Ascentage Pharma Group Inc. · NCT06051409A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Ph
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06401603Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Phase 3 · 24 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07152041
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.